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Background: Prostate cancer is one of the most common malignant diseases and is
characterized by heterogeneity in the clinical course. To date, there are no efficient
morphologic features or genomic biomarkers that can characterize the phenotypes
of the cancer, especially with regard to metastasis – the most adverse outcome.
Searching for effective surrogate genes out of large quantities of gene expression
data is a key to cancer phenotyping and/or understanding molecular mechanisms
underlying prostate cancer development.
Results: Using the maximum relevance minimum redundancy (mRMR) method on
microarray data from normal tissues, primary tumors and metastatic tumors, we
identifed four genes that can optimally classify samples of different prostate cancer
phases. Moreover, we constructed a molecular interaction network with existing
bioinformatic resources and co-identifed eight genes on the shortest-paths among
the mRMR-identified genes, which are potential co-acting factors of prostate cancer.
Functional analyses show that molecular functions involved in cell communication,
hormone-receptor mediated signaling, and transcription regulation play important
roles in the development of prostate cancer.
Conclusion: We conclude that the surrogate genes we have selected compose an
effective classifier of prostate cancer phases, which corresponds to a minimum
characterization of cancer phenotypes on the molecular level. Along with their
molecular interaction partners, it is fairly to assume that these genes may have
important roles in prostate cancer development; particularly, the un-reported genes
may bring new insights for the understanding of the molecular mechanisms. Thus
our results may serve as a candidate gene set for further functional studies.Background
Prostate cancer is one of the most frequently-occurred malignant diseases affecting human
health and life qualities [1]. In this cancer, metastasis (i.e. tumor cells escaping from the pri-
mary tissue and eventually colonizing a distant site) reflects the most adverse phase, which
commonly results in disruption of a complex set of biological processes, causing severe
bone pain and spinal cord complications [2,3]. Due to the heterogeneity of the disease,
there are currently no reliable morphologic features or genetic/genomic biomarkers that
can effectively discriminate tissue-confined primary and/or metastatic tumors, thus less is
known for the mechanisms underlying the development of metastatic disease.© 2014 Li et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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disease progression and/or identifying genetic/genomic surrogates for the tumor pheno-
types. In most of the studies, the phenotype of a tumor is defined by its phase [4,5]; and
identification of molecular surrogates underlying the different tumor phases is facilitated
by classification of samples from the respective phases (i.e. normal prostate, primary
tumor, and metastatic tumor). Since the different phases constitute the process of disease
progression, the surrogates (i.e. set of genes) that distinguish the phases (or classify sam-
ples from different phases) would certainly provide insights for understanding the molecu-
lar mechanisms of disease progression. For prostate cancer, gene expression microarray
studies have characterized expression profiles of primary cancers, metastatic cancers and
normal tissues [6-8]; in some cases, correlations between gene expressions and cancer
phases have been revealed [9]. The studies have further led to the finding that differential
gene expression profiles hold for metastatic androgen ablation resistant prostate cancer
(AARPC) and androgen-dependent metastatic cancers [10]. In general, these results have
gained important insights about metastatic prostate cancer, regarding to the changes in
expressions of genes involved in various biological processes, e.g. signal transduction, cell
cycle, cell adhesion, migration and mitosis, etc. [11,12]. Nonetheless, one important prob-
lem remains: previous studies describe the correlations of expression profiles and disease
phases in terms of hundreds of genes, whereas they seldom provide a convenient molecu-
lar measure (i.e. minimum predictor gene set) for accurate classification of prostate cancer
phases, especially with respect to metastasis. Such a predictor gene set would be a better
highlight for the mechanisms of prostate cancer.
To address this issue, we herein adopt a two-step pipeline widely-used in previous studies,
which includes machine learning to identify disease-related genes and pathway analysis to
reveal molecular interactions among the genes [13-16]. First, we utilize the machine learn-
ing strategy for accurate classification of prostate cancer phenotypes based on gene expres-
sion microarray data. Specifically, we use the minimum redundancy – maximum relevance
method (mRMR), a robust method with a broad spectrum of applications [13,17], to serve
our goal of identifying a largest-parsimony (i.e. minimum) surrogate (i.e. gene set) for pros-
tate cancer phases. Moreover, in order to focus more on the issue of metastasis, we not only
consider gene expression data of normal and (tissue-confined) primary prostate tumor tis-
sues [7], but also include a previously published dataset of metastatic tumor samples (i.e. tis-
sue samples excluding potentially uninformative stromal genes) in our study [11].
Furthermore, genes/proteins usually co-function with their interaction partners; thus
molecular interaction partners of disease-related genes are also candidates for further
studies. For this purpose, we pinpoint the identified surrogate genes in a molecular inter-
action network constructed based on STRING (Search Tool for the Retrieval of Interact-
ing Genes), which is a database providing resources of molecular interaction information
[18]; and we then identify by the shortest-path analysis a set of potential co-acting factors,
which may serve as candidate causal genes for further experimental studies.Materials and methods
Data source
The gene expression dataset was adopted from a research on prostate cancer by Chandran
et al. [11]. The data were with the Affymatrix GPL92 platform and generated from 167
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sues free of pathological alterations from organ donor and normal tissues adjacent to
tumor), 66 primary prostate tumors (PTs) and 24 metastatic tumors (MTs). All tissue
samples were acquired from the Health Sciences Tissue Bank of the University of
Pittsburgh Medical Center under stringent Institutional Review Board guidelines with
appropriate informed consent [11]. The data were downloaded from NCBI Gene
Expression Omnibus (GEO) with accession number GSE6919. The normalized expression
data were obtained directly from the GEO website, in which the data were normalized by
global scaling and analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix
default settings. In our machine learning procedure, we did not combine the expressions
from probes to genes; instead we obtained results at the probe level directly. We focused
our analysis on probes corresponding to protein coding genes.
Algorithm of mRMR & prediction engine
The minimum redundancy – maximum relevance (mRMR) algorithm was utilized
herein to select surrogate genes for prostate cancer progression. The major steps of
mRMR implementation were the same as we previously described [13]. The algorithm
aimed to balance features’ relevance to the prediction target and the redundancy be-
tween features. Both relevance and redundancy were quantified with mutual informa-
tion (MI), estimated as,
I x; yð Þ ¼ − 1
2
ln 1−ρ x; yð Þ2  ð1Þ
where I represented the MI and ρ was the correlation coefficient between the vari-ables x and y.
First, assume that y was the input variable, and X = { x1, …, xn } was the set of input
features. Given xi as the feature with the highest MI with the input variable, the feature
set (S) at the current step was then initialized by xi. Second, we selected the feature xj
with the best balance between highest relevance and lowest redundancy and added it to
S. It was achieved by maximizing the score q as follows,









We repeated the above steps until a desired solution length was reached. The mRMR
algorithm was implemented using the R package “mRMRe” [19].
We predicted the phenotype of an individual in three ways: 1) the phenotype of its near-
est neighbor; 2) the most-occurring phenotype of its five nearest neighbors; 3) the pheno-
type of its nearest clustering center of each phenotype group (for detailed results, see
Additional file 1: Table S1). According to Chou et al.’s studies [17,20], the distance be-
tween two individuals was calculated as follows,
d i1; i2ð Þ ¼ 1− e1⋅e2e1j j⋅ e2j j ð3Þ
where d was the distance, i1 and i2 were two samples, and e1 and e2 were the vectorsof selected features of i1 and i2, respectively.
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We used jackknife validation to estimate the prediction accuracy of the selected fea-
tures. The advantages of jackknife comparing with other validation methods, such as
independent-dataset validation and sub-dataset validation, were discussed previously
[17,20]. In jackknife validation, given X samples of a known outcome variable and N se-
lected features, for each sample we compared the known outcome with an estimated
outcome, which was computed based on the rest X - 1 samples. We defined the accur-
acy of a prediction using the following formula,
Accuracy ¼ TP þ TN
TP þ TN þ FP þ FN ð4Þ
where TP, TN, FP and FN represented the numbers of true positives, true negatives,
false positives and false negatives, respectively.
Furthermore, Incremental Feature Selection (IFS) was used to determine the number
of features for optimal prediction (Figure 1). As previously described [13], for N = 1 to
400 required number of features, each feature set was computed by mRMR and the
prediction accuracy was estimated using Jackknife validation. The set with the best pre-
diction accuracy and smallest feature number was regard as the final feature set. In this
study, a set with four genes was chosen and its prediction accuracy is 0.7202.
Molecular interaction network & shortest-path analysis
To reveal possible functional implications of the mRMR-selected genes, we explored
the shortest-paths among the genes in a background molecular network constructed
using the protein-protein interaction (PPI) data from STRING database (version 9.1)
(http://string-db.org) [18]. To identify the shortest-path between two genes/proteins,
we used Dijkstra’s algorithm and implemented it in the R package “igraph” [21]. The
resulting sub-network of PPIs representing the shortest-paths among the four mRMR-
selected genes (Figure 2) was visualized using Cytoscape (version 3.0.1) [22].
GO and KEGG pathway annotation
We carried out functional annotation for all the genes identified by mRMR and shortest-
path analysis based on GO and KEGG pathways. The functional annotations were imple-
mented using the web service of DAVID tools (version 6.7) [23], by which existence of
gene enrichments to certain functional modules/pathways could also be observed.
Results
A set of four genes presents the best accuracy for predictions of NTs vs. MTs and PTs
vs. MTs
In implementation of mRMR, we consecutively tested the predictor with one feature
(probes of gene expression array), two features, three features, etc., and the IFS result
was provided in Figure 1. In the IFS curves, X-axis is the number of probes used for
classification and Y-axis is the prediction accuracy (of the nearest-neighbor algorithm
evaluated by the Jackknife validation). As shown, the accuracy for classification of NTs vs.
MTs and PTs vs. MTs reaches the maximum when only four features are included, corre-
sponding to four genes annotated in the Ensemble Biomart database (TUBB6, MYEF2,























Figure 1 IFS curves determining the number of features. We used the IFS curves to determine the
number of features used in mRMR computation. “Prediction 1”, “Prediction 2” and “Prediction 3” refer to the
three prediction approaches, a vote of the top five nearest neighbors, the first nearest neighbor and nearest
clustering center of each phenotype group, seperately. It is noted that when using four genes, the prediction
accuracy reaches the maximum.
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genes in later sections.A PPI sub-network provides additional insights for the prostate cancer-related genes
Furthermore, we constructed an molecular interaction network with the PPI data from
STRING. We traversed all pairs of any two genes from the four surrogate (protein cod-
ing) genes identified by mRMR as described above; and we then calculated the shortest
paths between any pair of two proteins/genes using the Dijkstra’s algorithm. We even-
tually obtained a sub-network of STRING PPIs that contained all these shortest paths
(Figure 2). There are a total of 14 protein-protein interactions of 12 proteins, eight of
which correspond to genes other than the four mRMR-identified ones and they are all
annotated in the Ensemble Biomart database. We list these genes in Table 2 as an ex-
tended set of candidate regulatory factors of prostate cancer that are possibly co-acting
with the four mRMR-identified surrogate genes.Functional annotation of the identified genes
Using the functional annotation tool DAVID, we carried out Gene Ontology (GO) and
KEGG Pathway annotation for all the 12 identified genes (including the four mRMR-
selected genes and another eight ones traced in the shortest-path PPI network). The
results show that many genes are functioning to regulate transcription and/or tran-
scription factor activity (Table 3), echoing the previous finding that genes expressions
in (metastatic) prostate cancer are dictated by distinct transcriptional programs [12]. In
addition, the genes are also involved in pathways related to steroid hormone receptor
activity (Table 3). This is highly consistent with earlier studies that growth of prostate
cancer cells is dependent on the male hormone (i.e. androgen) and overly prolonged
changes of in vivo hormonal level (e.g. androgen deprivation therapy, ADT) causes the
emergence of androgen-independent (AI) cancer cells, which result in more malignancy
towards advanced or metastatic prostate cancer [24,25]. It is obvious that function of
hormone receptor plays a crucial role in prostate cancer progression; and our surrogate













Figure 2 PPI network of shortest-paths among the four mRMR-identified genes. We identified the
shortest-paths between each pair of the four mRMR-selected genes in the backgroud molecular interaction
(PPI) network constructed based on STRING. Symbols of proteins and their corresponding genes are used
interchangably herein. Rectangles colored in yellow are the four mRMR-selected genes/proteins; the others
represent interaction parnters locating on some shortest-paths among them.
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notated by both GO and KEGG pathways as relating to gap junction and regulation of cell
communication (Table 4). In fact, it is long recognized that gap junction-mediated inter-
cellular communication is required for cellular normality and breakdown of this commu-
nication is a hallmark of cancer [26,27]. Furthermore, earlier studies have shown that
intercellular communications and expressions of gap junction-forming proteins are largely
reduced or not detected in prostate cancer cells [28,29]. Therefore, our results have faith-
fully embodied the impact of cell communication dysregulation in prostate cancer.Discussion
In the present study, we applied an informatic approach to identify molecular surrogates
underlying the different phases of prostate cancer, which would facilitate deciphering the
Table 1 The four genes identified by mRMR
Probe ID Ensembl gene ID Ensembl protein ID Gene symbol Gene function
43355_s_at ENSG00000176014 ENSP00000318697 TUBB6 Microtube formation; gap junction
(intercellular communication)
55458_at ENSG00000104177 ENSP00000316950 MYEF2 Myelination repression
54033_at ENSG00000169116 ENSP00000370224 PARM1 Telomerase activity upregulation;
prostatic cancer cell immortalization
52890_at ENSG00000177542 ENSG00000177542 SLC25A22 Mitochondrial carrier;
energy metabolism
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SLC25A22, TUBB6, MYEF2 and PARM1. Data have shown that these genes ensure the
sample classification with the accuracy of more than 70% and the genes are annotated to
cancer-relevant functions/pathways. Thus the reasonability of our research is suggested.
In the results, two of the four genes (TUBB6, PARM1) are supported by literature for their
roles in prostate cancer; nonetheless, the other two (SLC25A22, MYEF2) are less known.
Therefore, due to the indication of our results, we believe that these two genes may also
sustain potentially role(s) during prostate cancer progression and they are worth being fo-
cused on for further experimental studies.
SLC25A22 is named as solute carrier family 25 (mitochondrial carrier: glutamate),
member 22. It is involved in the transport of glutamate across the inner mitochondrial
membrane (accompanied by H+ transportation), which facilitates the malate-aspartate
shuttle. The gene has also been validated by another dataset [30]. We hypothesize that the
functioning of malate-aspartate shuttle can provide extra energy to cancer cells for gaining
the growth advantage against native cells as well as escaping from the original site.
TUBB6 is a gene encoding a subtype of β-tubulins, the major constituent of micro-
tube, which plays fundamental roles in cell structure maintenance, formation of the mi-
totic spindle, transportation of chemicals, etc. Furthermore, TUBB6 is also functionally
associated with gap junctional intercellular communication (GJIC). In fact, the respect-
ive relationships between both tubulin and GJIC with metastasis of prostate/other cancers
have been studied. For instance, the level of tubulin affects the metastasis of colorectalTable 2 Genes on shortest-paths among the four mRMR-identified genes
Ensembl gene ID Ensembl protein ID Gene symbol Gene function
ENSG00000091831 ENSP00000206249 ESR1 Hormone receptor; ligand-activated
transcription factor
ENSG00000026025 ENSP00000224237 VIM Cytoskeleton formation and maintenance;
organization of cell attachment,
migration and signaling
ENSG00000138650 ENSP00000264360 PCDH10 Cadherin-related receptor
mediating cell-cell adhesion
ENSG00000152661 ENSP00000282561 GJA1 Gap junction (intercellular communication)
ENSG00000150991 ENSP00000344818 UBC Ubiquitination
ENSG00000151623 ENSP00000350815 NR3C2 Mineralocorticoid receptor;
ligand-dependent transcription factor
ENSG00000163848 ENSP00000353863 ZNF148 DNA-binding transcription factor;
regulator in cell growth and apoptosis
ENSG00000198888 ENSP00000354687 MT-ND1 Mitochondrial NADH oxidoreductase;
energy metabolism
Table 3 GO annotation for genes co-identified by mRMR and shortest-path analysis
Term Genes Count %*
GO: 0043565 ~ sequence-specific DNA binding ZNF148, ESR1, NR3C2, MYEF2 4 36. 364
GO: 0030528 ~ transcription regulator activity ZNF148, UBC, ESR1, NR3C2, MYEF2 5 45. 455
GO: 0010604 ~ positive regulation of
macromolecule metabolic process
ZNF148, UBC, ESR1, GJA1 4 36. 364
GO: 0010647 ~ positive regulation of cell communication UBC, ESR1, GJA1 3 27. 273
GO: 0003700 ~ transcription factor activity ZNF148, ESR1, NR3C2, MYEF2 4 36. 364
GO: 0003707 ~ steroid hormone receptor activity ESR1, NR3C2 2 18. 182
GO: 0004879 ~ ligand-dependent nuclear receptor activity ESR1, NR3C2 2 18. 182
GO: 0005496 ~ steroid binding ESR1, NR3C2 2 18. 182
GO: 0010628 ~ positive regulation of gene expression ZNF148, UBC, ESR1 3 27. 273
GO: 0005198 ~ structural molecule activity VIM, UBC, TUBB6 3 27. 273
*“%” refers to the percentage of genes in the total gene set.
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metastatic capacity [32-34]. Moreover, studies have also indicated that TUBB6 itself is
functionally related with the metastasis of various cancers. For instance, in a study using
60 cancer cell lines with different invasion abilities, TUBB6 is identified as an invasion-
associated (IA) gene [35]. Moreover, it is also identified as one of the 38 prognostic gene
expression signatures of node-positive breast cancer after systemic adjuvant chemotherapy
[36]. In addition, Champine et al. have shown that one of the potential mechanisms of
BRMS1-mediated metastasis suppression is the suppression of TUBB6 [37].
PARM1 is named as prostate androgen-regulated mucin-like protein 1. The gene reg-
ulates telomerase protein component 1 (TLP1) expression and telomerase activity, thus
enabling certain prostate cells to resist apoptosis. Multiple works have proved that
PARM1 is an important causal gene of prostate cancer [38-40]. It contributes to the
immortalization of prostatic cancer cells, which enhances the survival advantage against
the neighboring native cells and promotes metastasis. MYEF2 is myelin expression fac-
tor 2, which functions as a transcription repressor of the myelin basic protein (MBP).
Our results underline the importance of the gene for prostate cancer, although no dir-
ect relationship between MYEF2 and the cancer had been established yet.
Our findings have provided a concise picture of the metastasis of prostate cancer. Ac-
cording to Valastyan and Weinberg, the metastatic process includes 7 steps [41]: (1) in-
vade locally through surrounding extracellular matrix and stromal cell layers, (2)
intravasate through blood vessels, (3) survive during the transportation, (4) arrest at
distant organ sites, (5) extravasate into the parenchyma of distant tissues, (6) initially
survive in these foreign microenvironments in order to form micrometastases, and (7)
re-initiate their proliferative programs at metastatic sites. First, as a cancer cell, energy
is its priority (i.e. functional relation with SLC25A22). Step (1) and (2) of metastasis
need more mobility, for which tubulin will accommodate this task. PARM1 can en-
hance the survivability of cancer cells during the transportation and competing with
the native cells in the invaded environment.Table 4 KEGG annotation for genes co-identified by mRMR and shortest-path analysis
Pathway Genes Count %
hsa04540: Gap junction TUBB6, GJA1 2 18. 182
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their co-interacting genes in the PPI network contain existent or potential therapeutic
targets for cancers. In fact, Conde-Pueyo et al. suggest that TUBB6 forms a sythetic le-
thal (SL) association with the cancer-related gene BUB1, speculating that treatments
targeting the tubulin gene should be more efficient in cancers where BUB1 is mutated
[42]. Moreover, tubulins are existent targets of anti-cancer drugs, e.g. Paclitaxel and
vinca alkaloids (e.g. Vincristine and Vinblastine) in various cancers (including pros-
tatic). The drugs disrupt the formations of microtubules/mitotic spindles and hence in-
hibit the proliferations and metastases of cancer cells [43,44]. PARM1 is part of the
Golgi apparatus that is androgen-responsive, and researches demonstrate that the Golgi
apparatus embody new mechanisms of the androgen receptor (AR)-mediated signaling
and they are useful biomarkers for prostate cancer diagnosis/prognosis [45]. Moreover,
Golgi-targeting drugs have been shown to be effective in both androgen-dependent/-in-
dependent prostate cancers [45]. Given this foreground, PARM1 may have the potential
of a therapeutic target for prostate cancer. It is also noteworthy that although the other
two genes we identified (SLC25A22 andMYEF2) do not possess direct therapeutic utilities
at present, they may somehow implicate theoretical clues for cancer therapies. In fact,
members of the SLC25A family (e.g. SLC25A4/5/6) are existent drug targets for the treat-
ments of bone metastases in breast cancer and metastatic bone disease [46]; since prostate
cancer also exhibit bone metastasis [3], SLC25A22 may be worth being examined for po-
tential relations to the metastatic properties of prostate cancer. Meanwhile, MYEF2 has
been characterized as a downstream target modulated by the Wnt/β-catenin pathway;
since inhibition of Wnt/β-catenin signaling suppresses a number of cancers (e.g. multiple
myeloma, colorectal cancer, etc.) [47], the genes regulated by Wnt/β-catenin may provide
insights into the mechanisms of cancer developments and therapies.
Furthermore, in the PPI partners co-identified with the surrogate genes, ESR1 (estro-
gen receptor 1) is a widely known therapeutic target (for selective modulators, e.g.
Raloxifene, Tamoxifen, etc.) in breast cancer in female [48]; however, its roles in the
prostate cancer in male have not been revealed. In addition, NR3C2 (also known as the
mineralocorticoid receptor, MR) belongs to the same family with the androgen receptor
(AR, also known as NR3C4). Since they are co-interacting with PARM1 and MYEF2
(Figure 2), ESR1 and NR3C2 may also participate in prostate cancer along with the ex-
istent/potential targets. Moreover, other co-identified genes via PPI are also informative
for cancer researches. PCDH10 (protocadherin 10) is a potential target for demethyla-
tion drugs to achieve its reactivation, which may facilitate the therapies of a wide var-
iety of cancers (e.g. cervical, gastric, colorectal, breast cancers and leukemias) [49,50].
ZNF148 (also known as ZBP-89) regulates cell grwoth and apoptosis, having crucial
roles in the developments of many cancers (e.g. gastric, colorectal, breast cancers). It is
a potential target in cancer therapy as experiments show that ZNF148 is a tumor sup-
pressor capable of enhancing the killing effects of several anti-cancer drugs [51]. There-
fore, we hypothesize that these therapeutic targets may also have biological roles in
prostate cancer, or prostate cancer may have regulators that are in common with other
cancers. In addition,VIM (vimentin) is characterized as an invasion/metastasis factor in
tumor cells, which is transcriptionally regulated by HIF-1 [52]. GJA1 (gap junction protein,
alpha 1) involves in gap junction (GJIC), which plays important roles in cancer progression/
metastasis. MT-ND1 encodes a mitochondrial oxidoreductase (NADH dehydrogenase
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In fact, both gap junctions and mitochondria are emerging as therapeutic targets in
cancers nowadays [53,54].
The previous work of Chandran et al. has discovered hundreds of genes with differential
expression profiles [11]. In order to decipher the disease more concisely, we adopt the
mRMR algorithm, which can provide results with the largest parsimony. Our results have
showed that prostate cancer samples can be classified with only four genes, indicating that
although the cancer is a complex disease with hundreds of differentially-expressed genes,
these four genes may be the primary surrogates for the mechanism (s) underlying the dif-
ferent cancer phases. Moreover, these four genes (along with their PPI partners) turn out
having mechanistic/therapeutic implications in the prostatic or other cancers. Hence, in
order to characterize the development of prostate cancer (especially metastasis) and inves-
tigate the molecular mechanism (s), these genes could firstly be focused on in further
functional experiments.Conclusion
In all, we have characterized a small-sized predictor gene set for classification of prostate
cancer phases. Our results support the roles for specific genes involved in cell communi-
cation, hormone-receptor mediated pathways, and transcription regulation in (metastatic)
prostate cancer. To our knowledge, the gene set we computed is of the minimal size that
can rationally characterize prostate cancer phases; thus we hypothesize that these genes
potentially play important roles in the molecular mechanisms of prostate cancer develop-
ment. Furthermore, due to the small size, our predictor gene set can be a suitable candi-
date list for forthcoming functional experiments; meanwhile, it might possess potential
value for other relevant studies (e.g. drug target selection).Additional files
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